Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205868 | 0.77 | PPARA (0.38) | PPARASYKCTSLHTR2CP2RX7 | |
| SCHEMBL2470236 | 0.73 | HDAC3 (0.54) | SYKCTSLKDM1A | |
| SCHEMBL5729683 | 0.73 | SYK (0.43) | PPARASYKCTSLHTR2CKLK7 | |
| SCHEMBL17188016 | 0.71 | HDAC3 (0.50) | SYKCTSLKDM1ARORC | |
| SCHEMBL2670184 | 0.71 | PDE4B (0.40) | SYKCTSLHTR2CKDM1APDE4B | |
| SCHEMBL19718088 | 0.71 | MEN1 (0.47) | SYKCTSLKDM1A | |
| SCHEMBL7507956 | 0.70 | MEN1 (0.49) | SYKCTSLKDM1A | |
| SCHEMBL19718197 | 0.70 | MEN1 (0.46) | SYKCTSLKDM1A | |
| SCHEMBL31454371 | 0.70 | SYK (0.53) | PPARASYKCTSLCTSS | |
| SCHEMBL14828963 | 0.70 | SYK (0.46) | PPARASYKCTSLHTR2CRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020459-B1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-20020077345-A1 | Cis-substituted aminocycloalkylpyrrolidine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-06-20 | — | — | US | disclosed |
| EP-1020459-A1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077345-A1 | Cis-substituted aminocycloalkylpyrrolidine derivatives | Q6ZSR9, ARG1, ASNS | PPARA 1055/4885SYK 2935/4885CTSL 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.